Summary E1000, the most drug-resistant subline from the E-series (CCRF-CEM/E16 to E1000), has been previously shown to express high mRNA levels from two ABC transporter genes associated with multidrug resistance, ARA and MRP. The expression and amplification of both genes has now been characterized for each member of the E-series of drug-resistant sublines and is reported here. Both ARA [detected by reverse transcriptase polymerase chain reaction (RT-PCR)] and MRP (detected by Northern blot analysis) were expressed at low levels in the sensitive parental CEM cell line. An equivalent level of MRP mRNA expression was detected throughout the CEM, E16, E25 and E50 sublines, and there was increasing expression in the El 00, E200 and El 000 sublines. ARA expression was not detected in the El 6, E25, E50 and E100 sublines but was detected by both RT-PCR and Northern blot analysis in the E200 and E1000 sublines. Southern blot analysis indicated the increased levels of MRP and ARA expression resulted from gene amplification and that MRP was first amplified in the E100 subline and ARA in the E200 subline, suggesting that the two genes were not initially co-amplified. Cytogenetic analysis of E1000 cells demonstrated a large addition to chromosome 1 6p, around the region where the ARA and MRP genes are located. Increased expression of ARA is associated with increased colchicine resistance in the E-series of sublines and combined with MRP may account for their resistance phenotype.
The occurrence of the multidrug resistance (MDR) phenotype is still a major obstacle to the successful treatment of cancer. It now appears that overexpression of a number of ATP-binding cassette (ABC) transporter proteins is, at least partially, responsible for the MDR phenotype. Two ABC transporters that have been shown to confer drug resistance are P-glycoprotein (Gottesman and Pastan, 1993) and the multidrug resistance-associated protein (MRP) (Grant et al, 1994) . Other ABC transporters that have recently been implicated in drug resistance include the human canalicular multispecific organic anion transporter (c-MOAT) (Taniguchi et al, 1996) , ABC-C (Klugbauer and Hoffman, 1996) , the transporter associated with antigen processing (TAP) (Izquierdo et al, 1996) and the anthracycline resistance-associated (ARA) protein (Longhurst et al, 1996) .
ABC transporters have been implicated in MDR as a result of studies carried out on MDR cell sublines produced by exposure to stepwise increasing drug concentrations. The E-series of MDR cell sublines was developed by treatment of the T-cell leukaemia cell line CCRF-CEM (Foley et al, 1965) with increasing levels of the anthracycline epirubicin (Davey et al, 1995) . This series contains sublines displaying increasing levels of MDR, beginning with the E16 (resistant to 16 ng ml-' epirubicin) through to the EI000 subline (resistant to 1000 ng ml-' epirubicin). Thus, the E-series provides a model in which to determine the relationship between the level of MDR and the expression of MDR mechanism(s).
Previously, we have shown that MRP expression parallels the observed increase in drug resistance in the members of the Eseries (Davey et al, 1995) and that both ARA and MRP are amplified in the EIOOO subline (Longhurst et al, 1996) . ARA has recently been mapped to human chromosome 16p 13.1 (Dr B Kuss, personal communication) in the vicinity of MRP at 16p 13.13 (Cole et al, 1992) and confirmed by the recent release of sequence data from human chromosome 16pll3 (GenBank accession code U91318). The amplification states of the ARA and MRP genes and the level of ARA expression have not been reported in the remaining members of the E-series. This study reports the relationships between ARA and MRP gene amplification and expression and drug cross-resistance in the E-series of sublines.
MATERIALS AND METHODS Cell lines
The human leukaemia cell line CCRF-CEM (CEM) (Foley et al, 1965) , and its epirubicin selected drug-resistant sublines, E16, E25, E50, E100, E200 and E1000 (E-series) (Davey et al, 1995) , were maintained as suspension cultures at 37°C in a humidified atmosphere with 5% carbon dioxide, either in RPMI-1640 medium (Trace Biosciences, Sydney, Australia) containing 10% fetal calf serum (Trace Biosciences) and supplemented with 10 mm sodium hydrogen carbonate and 20 mM Hepes or in alpha-MEM (ICN, Sydney, Australia), as previously described (Davey et al, 1995) . Exponentially growing cells were used for all experiments and all cell cultures were free of mycoplasma. DNA probes cDNA inserts were excised from plasmid constructs by restriction enzyme digestion and the gel-purified inserts were labelled with [32P]dCTP using a random primed DNA labelling kit (Boehringer Mannheim, Sydney, Australia). The plasmid pmrplO.1 was gratefully obtained from SPC Cole and RG Deeley (Cole et al, 1992) and the 1000-bp EcoRl nucleotide fragment was used to probe for MRP. The ARA probe consisted of a 1000-bp SacI-NotI restriction fragment isolated from the clone encoding ARA (Longhurst et al, 1996) . A 600-bp fragment of mouse ,-actin, excised by digestion with PstI, was used to standardize RNA loading.
British Journal of Cancer (1998) Southern blot analysis Genomic DNA was extracted from each subline as described previously (Sambrook et al, 1989) . DNA was digested with the restriction enzyme Xba I and 10 ,ug of each digest separated by electrophoresis in a 0.5% agarose gel. Separated DNA was transferred to Zetaprobe GT membrane (BioRad, Sydney, Australia) and hybridization carried out as described previously (Longhurst et al, 1996) at 65°C.
Northern blot analysis
Total RNA was extracted from each subline using guanidine thiocyanate as described previously (Chomcyznski and Sacchi, 1987) . Extracted RNA was separated by electrophoresis in % agarose gels and transferred to Zetaprobe GT membrane as described previously (Sambrook et al, 1989) . Aliquots of either 20 ,ug or 30 jig of total RNA were loaded in each well for hybridization with the MRP and ARA probes respectively. Hybridizations were carried out at 42°C in 50% formamide as described by Sambrook et al ( 1989) .
Reverse transcription polymerase chain reaction (RT-PCR)
Reverse transcription reactions were carried out on 2.5 jg total RNA, extracted as described above. Reactions were performed in a 20-gl reaction volume using 1 gM random hexamers (Gibco-BRL, 
Cytotoxicity assays
The cytotoxicity of each drug was determined using an MTT cell viability assay (Marks et al, 1992) . Each determination was in triplicate and all experiments were repeated at least once. The IC50 value (drug concentration causing 50% decreased in MTT production) was determined and the relative resistance was calculated by dividing the IC () for each subline by that of the CEM line. Figure IA shows a partial GTL-banded karyotype of two cells from the E1000 subline. Clearly evident is a large addition to 16p, shown by whole-chromosome paint to comprise chromosome 16 material, except for the extreme distal region (Figure 1 B) .
RESULTS

Amplification of ARA and MRP
Southern blots of DNA extracted from each member of the Eseries of drug-resistant sublines and the parental CEM cell line were assayed with cDNA probes for ARA and MRP. An equivalent level of ARA hybridization was detected in the CEM, E16, E25, E50 and E100 cell lines and increased hybridization was detected for the E200 and E1000 cell lines (Figure 2A ), suggesting that ARA was amplified in the last two sublines. The level of MRP hybridization to DNA from CEM, E16, E25 and E50 sublines did not change, however there was increased hybridization detected in the E100, E200 and EIOOO cell lines ( Figure 2B ), suggesting that MRP was amplified in these sublines. Expression of ARA and MRP Northern blot analysis of total RNA extracted from the E-series of drug-resistant sublines demonstrated that ARIA mRNA could only be detected in the E200 and E1000 sublines ( Figure 3A ). Longer exposure time of the autoradiograph did not result in detection of ARA mRNA in the less drug-resistant sublines (results not shown). A low level of MRP mRNA was detected in the CEM cells and similar levels were detected in the E16, E25 and E50 sublines ( Figure 3B ). Increasing levels of MRP mRNA were detected in the EI00, E200 and EI000 sublines. Probing with 1-actin demonstrated that all RNA loadings were equal (Fig 3A and B) . RT-PCR was carried out on total RNA extracted from each member of the E-series. PCR with the ARA primer pair resulted in a product of the expected size (324 bp) detected faintly in the CEM sample and clearly in both the E200 and EIOOO samples (Figure 4) . A second band, of less than 300 bp, observed in the CEM lane disappeared with decreasing concentration of Mg2+ in the PCR reaction (results not shown). To ensure that the negative results observed with the other sublines were not due to template problems, control PCR reactions with the 3-actin primer pair were carried out on all reverse-transcribed samples. Figure 4 demonstrates that a band of the expected size (661 bp) was observed in all samples, indicating that each reverse-transcribed sample could be amplified in the PCR. In addition, template-negative PCR controls gave no PCR products. Therefore, ARA expression was not detected in the E16, E25, E50 and EIOO sublines by RT-PCR.
Drug cross-resistance profiles of the E-series of sublines
Each subline from the series was assayed for resistance to treatment with actinomycin D, vinblastine, colchicine, vincristine, daunorubicin, doxorubicin, epirubicin and etoposide, and the fold resistance relative to the CEM parent cell line was calculated ( Figure 5 ). Each subline was resistant to all the anthracyclines and etoposide with the E16, E25 and E50 sublines exhibiting similar levels of resistance (three-to tenfold). The E100, E200 and E1000 sublines showed increasing resistance to these drugs and to vincristine. Resistance to colchicine was first detected in the E200 subline and this was increased in the EIOOO subline.
DISCUSSION
The results presented here have demonstrated that the amplification of ARA in the E200 and EIOOO sublines plus amplification of MRP in the E100, E200 and El000 sublines (Figure 2 ) most probably account for the increased expression of these two genes as shown by Northern blot analysis of ARA and MRP expression (Figure 3 ) and in earlier analyses of MRP expression (Davey et al, 1995) . In the E1OO0 subline, this amplification is associated with a large addition to chromosome 16p (Figure lA) , which contains much chromosome 16 material as demonstrated by the chromosome 16 paint (Figure I B) . This segment comprises a novel banding pattern, implicating multiple and complex rearrangements. Changes of this nature have been associated with other examples of gene amplification, mediated through the breakagefusion-bridge (or BFB) cycle (Smith et al, 1992; Toledo et al, 1992) . For a number of cell generations, this cycle engenders a massive and sustained increase in the duplication and deletion rate within the involved chromosome(s). As such, the BFB cycle The BFB cycle can thus be regarded as of oncogenic significance, similar in potential to mutations that increase the mutation rate at the molecular rather than the cytogenetic level (Eshleman and Markowitz, 1996; Loeb, 1997) . Amplifications arising through the BFB cycle accrue gradually, originating as gene duplications only (Smith et al, 1992) . However, the relatively high levels of gene amplification seen in cultured drug-resistant sublines can also be achieved through the BFB cycle, given that the BFB can proceed in vitro over a much greater number of cell generations than occur in vivo, during the clinical course of malignancy. Both ARA and MRP have been mapped to the short arm of chromosome 16. MRP has been localized to 16pll3.13 (Cole et al, 1992) and ARA has been localized to l6pl3.1 (Dr B Kuss, personal communication). The close proximity of the two genes suggests that they could be co-amplified. However, the observation that MRP is first amplified in the E1OO subline and ARA and MRP are amplified in the E200 subline indicates that the co-amplification was secondary to and, to some extent, independent of the original MRP amplification in the E100 subline. In support of this, cytogenetic analyses of the EIOO subline show another 16p addition, differing in size and banding pattern from that observed in the EIO1O subline (Peters et al, manuscript in preparation). The presence of multiple amplifications, arising in related but distinct cytogenetic subclones, is also compatible with amplification via the BFB cycle (Ma et al, 1993) .
Others have reported that MRP amplification corresponds to increased MRP expression in a variety of MDR sublines (Cole et al, 1992; Krishnamachary et al, 1994; Slapak et al, 1994; Binaschi et al, 1995; Slovak et al, 1995) . The MDR human small-cell lung cancer sublines, GLC4/ADR and H69/AR, contain amplified MRP in double-minute chromosomes and additions to various chromosomes other than 16 (Eijdems et al, 1995; Slovak et al, 1993) . The 2080 GM O'Neill et al MDR HT1080/DR4 fibrosarcoma subline contains amplified MRP in additions to chromosome 7 (Slovak et al, 1995) . The MDR HL60/AR subline has additions to chromosome 7 but also has augmentation of the 16p13.1 region containing the MRP gene (Cole et al, 1992) . In comparison, the EIOOO subline appears to contain no double-minute chromosomes but a large augmentation of 16p. These examples of sublines containing amplification of MRP were all selected with a DNA disrupting drug, which may initiate the amplification process by causing chromosome breakage and reciprocal gains and losses of genetic material (Ma et al, 1993) . Cells carrying amplifications resulting from breaks in the vicinity of drug resistance loci may then be selected for by the presence of the drug. This selective advantage may not just involve MRP but it may also include other putative drug-resistance genes near this region on 16p such as ARA, the major vault protein or lung resistance protein gene, LRP, located at l6pl1.2 (Slovak et al, 1995) and ABC-C located at 16plI3.3 (Klugbauer and Hoffman, 1996) .
The drug cross-resistance of each member of the E-series, presented here ( Figure 5 ) and reported previously (Davey et al, 1995) , suggests that MDR has developed in two phases. The first phase, corresponding to lower levels of MDR, is observed in the E16, E25 and E50 sublines. This is associated with no significant change in MRP expression relative to that in the CEM cells, which suggests that either MRP is not involved in this low level MDR or, alternatively, the 'activity' of MRP may be altered in these sublines. The first phase appears also to be associated with decreased ARA expression as RT-PCR detected ARA mRNA in the CEM cells but not in the E16, E25 and E50 sublines (Figure 4 ). It therefore is unlikely that ARA is involved in low-level MDR in the E-series. The second phase represents the increasing resistance observed in the EI00, E200 and E1000 sublines. This is associated with increased MRP expression in these sublines and increased ARA expression in the E200 and E1000 sublines. Although there is a progressive increase in resistance to several drugs in the El00, E200 and E1000 sublines, only increasing colchicine resistance reflects ARA expression in the E200 and EIOO sublines. This raises the possibility that ARA may play some part in colchicine resistance in these sublines either through self-association or in association with MRP.
